Baidu
map

Hepatology:非酒精性脂肪肝患者可能导致心衰风险

2015-08-21 徐媛媛 MedSci原创

非酒精性脂肪肝(NAFLD)和心力衰竭(HF)导致高心血管死亡率。非酒精性脂肪肝(NAFLD)与亚临床心肌重构及功能障碍是否相关,目前尚未知晓。 研究人员对2713名CARDIA患者进行横断面多中心分析。所收纳的患者中有8.8%为女性,48%为黑人,NAFLD患病率为10%(n=271)。研究人员通过计算机断层扫描(CT)进行肝部脂肪量化,通过超声斑点追踪成像技术测定心肌



非酒精性脂肪肝(NAFLD)和心力衰竭(HF)导致高心血管死亡率。非酒精性脂肪肝(NAFLD)与亚临床心肌重构及功能障碍是否相关,目前尚未知晓。

研究人员对2713名CARDIA患者进行横断面多中心分析。所收纳的患者中有8.8%为女性,48%为黑人,NAFLD患病率为10%(n=271)。研究人员通过计算机断层扫描(CT)进行肝部脂肪量化,通过超声斑点追踪成像技术测定心肌张力。使用左室整体纵向应变(GLS)绝对峰值对亚临床左室收缩功能障碍进行定义。
研究结果显示,与无NAFLD的患者相比,NAFLD患者的舒张早期充盈速率较低(10.8±2.6 vs.11.9±2.8 cm/s),且左室充盈压较高(E/e':7.7 ± 2.6 vs. 7 ± 2.3),绝对GLS较差(14.2 ± 2.4% vs. 15.2 ± 2.4%,P值均 < .0001)。NAFLD患者心输出量更高,校正人体表面积之后有所减弱。经校正,NAFLD心衰风险因素或BMI后仍与亚临床心肌重构及功能障碍有关(P < 0.01),表明诊断NAFLD可能有助识别心衰发病风险升高的个体。

非酒精性脂肪肝(NAFLD)与亚临床心肌重构及功能障碍独立相关,而且可能与心衰有关。

原始出处

VanWagner LB1,2, Wilcox JE1,3, Colangelo LA1, Lloyd-Jones DM1,3, Carr JJ4, Lima JA5, Lewis CE6, Rinella ME2, Shah SJ3.Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.Hepatology. 2015 Apr 24

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1676279, encodeId=973516e627983, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Sun Sep 06 14:02:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980412, encodeId=26aa198041262, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 14 04:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673247, encodeId=1ca016e32477c, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Wed Sep 02 03:02:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389436, encodeId=497e138943611, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426616, encodeId=95b51426616ea, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1676279, encodeId=973516e627983, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Sun Sep 06 14:02:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980412, encodeId=26aa198041262, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 14 04:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673247, encodeId=1ca016e32477c, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Wed Sep 02 03:02:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389436, encodeId=497e138943611, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426616, encodeId=95b51426616ea, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1676279, encodeId=973516e627983, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Sun Sep 06 14:02:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980412, encodeId=26aa198041262, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 14 04:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673247, encodeId=1ca016e32477c, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Wed Sep 02 03:02:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389436, encodeId=497e138943611, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426616, encodeId=95b51426616ea, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1676279, encodeId=973516e627983, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Sun Sep 06 14:02:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980412, encodeId=26aa198041262, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 14 04:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673247, encodeId=1ca016e32477c, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Wed Sep 02 03:02:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389436, encodeId=497e138943611, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426616, encodeId=95b51426616ea, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1676279, encodeId=973516e627983, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Sun Sep 06 14:02:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980412, encodeId=26aa198041262, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 14 04:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673247, encodeId=1ca016e32477c, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Wed Sep 02 03:02:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389436, encodeId=497e138943611, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426616, encodeId=95b51426616ea, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Aug 23 02:02:00 CST 2015, time=2015-08-23, status=1, ipAttribution=)]
    2015-08-23 gwc384

相关资讯

心脏病重大里程碑!诺华心衰药Entresto(LCZ696)获FDA批准!

瑞士制药巨头诺华(Novartis)监管方面收获重大里程碑,该公司备受瞩目的慢性心衰药物Entresto(前称LCZ696)近日提前6周获得FDA批准,用于射血分数降低的心力衰竭(heart failure)患者,降低心血管死亡和心衰住院风险。Entresto是一种首创新药,以多种方式作用于心脏的神经内分泌系统,该药是过去25年内心衰治疗领域的一个伟大突破,有望成功动摇过去10年未被修改的心衰治疗

《急性心衰院前和院内早期管理指南》发布及要点

5月21日,《欧洲心脏杂志》(European Heart Journal)刊发了由欧洲心脏学会(ESC)心力衰竭委员会、欧洲急诊治疗学会和流行病学急诊治疗学会联合制定的《急性心力衰竭院前和院内早期的管理指南》(简短版本). 一、急性心衰早期诊疗指南之病房治疗要点 病房治疗及ICU/CCU治疗要点 1.若患者存在显著呼吸困难或血流动力学不稳定状态,应将患者安置于可立即开展心肺复

JACC Cardiovasc Interv:新型ARTO系统治疗功能性二尖瓣返流安全有效

新型ARTO系统可改善二尖瓣返流(FMR),因此,本研究评估了新型ARTO系统对心力衰竭患者和功能性二尖瓣返流的治疗效果。 MAVERIC试验是一项前瞻性,非随机化的研究。关键入选标准为患者均为收缩性心衰、NYHA心功能II~IV级、功能性二尖瓣返流等级大于2级、左心室射血分数小于等于40%、左室舒张末期内径在50 mm~75 mm之间。主要安全性终点是30天主要不良事件,有效性终点为二尖瓣返流

Nature Commun:小分子可促进缓解心脏衰竭

在心脏细胞中,心肌肌质网的钙离子相关的ATP合成酶(SERCA2a)的表达和活性的降低,被认为是心脏衰竭的标志。这个酶(SERCA2a)是一个与钙离子循环相关的关键性转运离子泵。之前他们发现了一种转录后修饰,即可反转的SUMO化修饰(类似于泛素化修饰),可以调节酶SERCA2a的功能进而影响心脏的功能。这种SUMO修饰可能在多方面影响着细胞的功能。就这个酶SERCA2a而言,存在着多种小的SUMO

JACC Heart Fail:急性失代偿性心衰(ADHF)患者β受体阻滞剂治疗不能停

以往的研究中,显示停用β受体阻滞剂会增加急性失代偿性心衰(ADHF)患者的死亡率和再入院风险,但并没有进行全面的分析。本研究评估并分析了β受体阻滞剂对急性失代偿性心衰(ADHF)患者的影响。 研究人员通过检索PubMed, EMBASE和COCHRANE电子数据库收纳了来自2000年到2015年1月期间发表的相关研究,这些研究主要比较继续和中断β受体阻滞剂治疗的急性失代偿性心衰研究。 共5项观

基因治疗再遇滑铁卢,Celladon心衰药物二期临床失败

今天下午美国生物制药公司Celladon宣布其心衰药物Mydicar 在一个叫做CUPID2二期临床彻底失败,错过实验一级和二级终点。实验一级终点为心衰诱发住院事件,二级终点为全因死亡、心脏移植、和体外循环支持治疗事件。 Mydicar是一个通过病毒递送SERCA2a基因的药物,用于严重心衰病人。慢性心衰是市场亟需新药的一个领域,已经20年没有新药上市。SERCA2a基因的蛋白产品是一个AT

Baidu
map
Baidu
map
Baidu
map